ArticleMedicine in drug discovery2021
AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate.
Article in Medicine in drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Camphor-10-Sulfonamide Amino Acid Esters: Synthesis, Antiviral Evaluation, and Molecular Docking Insights.International journal of molecular sciences · 2026Article
- AΙ-Driven Drug Repurposing: Applications and Challenges.Medicines (Basel, Switzerland) · 2025Review
- Developing an Improved Cycle Architecture for AI-Based Generation of New Structures Aimed at Drug Discovery.Molecules (Basel, Switzerland) · 2024Article
- Innovative applications of artificial intelligence during the COVID-19 pandemic.Infectious medicine · 2024Review
- In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Main Protease among a PubChem Database of Avian Infectious Bronchitis Virus 3CLPro Inhibitors.Biomolecules · 2023Article
- Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network.Multimedia tools and applications · 2023Article
- Innovative applications of artificial intelligence in zoonotic disease management.Science in One Health · 2023Review
- Sulfonamides with Heterocyclic Periphery as Antiviral Agents.Molecules (Basel, Switzerland) · 2022Review
- Cheminformatics Bioprospection of Broad Spectrum Plant Secondary Metabolites Targeting the Spike Proteins of Omicron Variant and Wild-Type SARS-CoV-2.Metabolites · 2022Article
- Deep Learning Promotes the Screening of Natural Products with Potential Microtubule Inhibition Activity.ACS omega · 2022Article
- Misconceptions and associated factors of COVID-19 infection among internally displaced persons in Sudan.Journal of public health in Africa · 2022Article
- COVID-19 Diagnosis: A Review of Rapid Antigen, RT-PCR and Artificial Intelligence Methods.Bioengineering (Basel, Switzerland) · 2022Review
- Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
- Machine learning enabled identification of potential SARS-CoV-2 3CLpro inhibitors based on fixed molecular fingerprints and Graph-CNN neural representations.Journal of biomedical informatics · 2021Article
- Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2.Current research in pharmacology and drug discovery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsOver the past few years, AI has been considered as potential important area for improving drug development and in the current urgent need to fight the global COVID-19 pandemic new technologies are even more in focus with the hope to speed up this process. The purpose of our study was to identify the best repurposing candidates among FDA-approved drugs, based on their predicted antiviral activity against SARS-CoV-2. MATERIALS AND
methodsThis article describes a drug discovery screening based on a supervised machine learning model, trained on KEY
findingsOur study identified zafirlukast as the best repurposing candidate for COVID-19. SIGNIFICANCE: Zafirlukast could be potent against COVID-19 both due to its predicted antiviral properties and its ability to attenuate the so called
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.